^
    Back
    Association details:
    Biomarker:GABARAP deletion
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application

    Published date:
    11/06/2019
    Excerpt:
    In conclusion, our studies demonstrate the clinical benefits of BTZ-induced ICD in MM; and that loss-of-function of GABARAP, particularly in HR patients with 17p deletion, abrogates induction of antitumor immunity after drug exposure.
    DOI:
    https://doi.org/10.1182/blood-2019-127845